Phase II Poor Responder Study FV1.0 27Aug2010

• Research type

  Research Study

• Full title

  Recombinant Human Insulin-like Growth Factor (rhIGF-1) and Growth Hormone (rhGH) Combination Therapy of Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and Poor Response to First Year of Growth Hormone Therapy: A Phase II, Prospective, Randomized, Open-label, Multi-Centre, Parallel Group Add-On Study Comparing a Flexible rhIGF-1 Dose and Fixed rhGH Dose vs. Fixed rhGH Dose Therapy.

• IRAS ID

  67691

• Contact name

  Assunta Albanese

• Contact email

  assunta.albanese@stgeorges.nhs.uk

• Sponsor organisation

  Ipsen Pharma

• Eudract number

  2010-020742-10

• ISRCTN Number

  Not Submitted

• Research summary

  Research Summary not published at request of researcher

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  11/H0720/5

• Date of REC Opinion

  9 May 2011

• REC opinion

  Further Information Favourable Opinion